Arkolith/Insider Trading/ATHA/Form 4

Litton Mark James

President and CEO, DirectorAthira Pharma, Inc. (ATHA) · full profile →Form 4 · filed Jan 3, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$14K
Net Open-Market Flow
-$14K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 2, 2025Sell(S)25K$0.56$14K243K
Dec 31, 2024Option exercise(M)108K—$0268K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 31, 2024Option exercise(M)108K—$0217K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-25-000536) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML